SAP Biomarker Analysis for Vascular Disrupting Agent Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vascular disrupting agents (VDAs) have not met objectives for increasing overall survival or progression-free survival in clinical studies, indicating a need for predictive biomarkers to identify responsive cancer patients.
Innovation Solution
The method involves analyzing changes in biological markers such as Serum Amyloid P (SAP) levels before and after administration of a vascular disrupting agent to predict patient response, specifically using a ratio of post-administration to pre-administration levels to determine if a patient will experience an increase in progression-free survival.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vascular disrupting agents are administered to cancer patients, then tumor vasculature is disrupted and blood flow is inhibited, but overall survival and progression-free survival do not increase
Solution Approach 1:
The patent applies preliminary action by measuring SAP levels before VDA administration to identify patients who are likely to respond to treatment. This predictive biomarker measurement allows for patient selection before treatment begins, enabling the VDA to be administered only to patients who will benefit, thereby improving overall survival and progression-free survival outcomes.
2Reliability
If vascular disrupting agents are administered to cancer patients, then tumor vasculature is disrupted, but progression-free survival does not increase
Solution Approach 1:
The patent measures SAP levels before VDA administration to predict treatment response. By identifying patients with high SAP levels who are likely to respond to vascular disruption, the treatment can be selectively administered to improve progression-free survival outcomes.
Solution Approach 2:
The patent uses SAP level changes as a feedback mechanism to assess treatment response. By comparing pre- and post-treatment SAP levels, the system provides feedback on whether the VDA was effective in disrupting tumor vasculature, allowing for treatment optimization and patient selection.
3Reliability
If predictive biomarkers are identified to select responsive patients, then treatment effectiveness is improved, but treatment selection complexity increases
Solution Approach 1:
The patent focuses on a single biomarker parameter (SAP level) rather than multiple complex parameters. By using one measurable parameter to predict treatment response, the system simplifies patient selection while maintaining high reliability in identifying responsive patients.
Data Source
Figure 1
Figure 2A~2B
Figure 3A~3B
AI summary
The present invention relates to the biological markers SAP, SHBG, Myoglobin, MMP-9, and SCF that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present invention relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.